High Central Pulse Pressure Is Independently Associated With Adverse Cardiovascular Outcome The Strong Heart Study

被引:240
作者
Roman, Mary J. [1 ]
Devereux, Richard B. [1 ]
Kizer, Jorge R. [1 ]
Okin, Peter M. [1 ]
Lee, Elisa T. [2 ]
Wang, Wenyu [2 ]
Umans, Jason G. [3 ]
Calhoun, Darren [3 ]
Howard, Barbara V. [3 ]
机构
[1] Weill Cornell Med Coll, Div Cardiol, New York, NY 10021 USA
[2] Univ Oklahoma, Hlth Sci Ctr, Ctr Amer Indian Hlth Res, Oklahoma City, OK USA
[3] Medstar Res Inst, Washington, DC USA
关键词
blood pressure determination; elasticity; hypertension; detection and control; vasculature; BLOOD-PRESSURE; AMERICAN-INDIANS; DISEASE; TRIAL; MORTALITY; EVENTS; RISK;
D O I
10.1016/j.jacc.2009.05.070
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives This study was designed to facilitate clinical use of central pulse pressure (PP). We sought to determine a value that might predict adverse outcome and thereby provide a target for assessment of intervention strategies. Background We previously documented that central PP more strongly relates to carotid hypertrophy and extent of atherosclerosis and, more importantly, better predicts incident cardiovascular disease (CVD) than brachial PP. Methods Radial applanation tonometry was performed in the third Strong Heart Study examination to determine central blood pressure. Cox regression analyses were performed using pre-specified covariates and quartiles of central and brachial PP. Results Among 2,405 participants without prevalent CVD, 344 suffered CVD events during 5.6 +/- 1.7 years. Quartiles of central PP (p < 0.001) predicted outcome more strongly than quartiles of brachial PP (p = 0.052). With adjustment for covariates, only the event rate in the fourth quartile of central PP (>= 50 mm Hg) was significantly higher than that in the first quartile (hazard ratio [HR]: 1.69, 95% confidence interval [CI]: 1.20 to 2.39, p = 0.003). Central PP >= 50 mm Hg was related to outcome in both men (HR: 2.06, 95% CI: 1.39 to 3.04, p < 0.001) and women (HR: 2.03, 95% CI: 1.55 to 2.65, p < 0.001); in participants with (HR: 1.84, 95% CI: 1.41 to 2.39, p < 0.001) and without diabetes (HR: 1.91, 95% CI: 1.29 to 2.83, p = 0.001); and in individuals younger (HR: 2.51, 95% CI: 1.59 to 3.95, p < 0.001) and older (HR: 1.53, 95% CI: 1.19 to 1.97, p = 0.001) than the age of 60 years. Conclusions Central PP >= 50 mm Hg predicts adverse CVD outcome and may serve as a target in intervention strategies if confirmed in other populations and in prospective studies. (J Am Coll Cardiol 2009; 54: 1730-4) (c) 2009 by the American College of Cardiology Foundation
引用
收藏
页码:1730 / 1734
页数:5
相关论文
共 21 条
[1]   Central blood pressure measurements and antihypertensive therapy a consensus document [J].
Agabiti-Rosei, Enrico ;
Mancia, Giuseppe ;
O'Rourke, Michael F. ;
Roman, Mary J. ;
Safar, Michel E. ;
Smulyan, Harold ;
Wang, Ji-Guang ;
Wilkinson, Ian B. ;
Williams, Bryan ;
Vlachopoulos, Charalambos .
HYPERTENSION, 2007, 50 (01) :154-160
[2]   Association between local pulse pressure, mean blood pressure, and large-artery remodeling [J].
Boutouyrie, P ;
Bussy, C ;
Lacolley, P ;
Girerd, X ;
Laloux, B ;
Laurent, S .
CIRCULATION, 1999, 100 (13) :1387-1393
[3]   Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure [J].
Chobanian, AV ;
Bakris, GL ;
Black, HR ;
Cushman, WC ;
Green, LA ;
Izzo, JL ;
Jones, DW ;
Materson, BJ ;
Oparil, S ;
Wright, JT ;
Roccella, EJ .
HYPERTENSION, 2003, 42 (06) :1206-1252
[4]   Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE):: a randomised trial against atenolol [J].
Dahlöf, B ;
Devereux, RB ;
Kjeldsen, SE ;
Julius, S ;
Beevers, G ;
de Faire, U ;
Fyhrquist, F ;
Ibsen, H ;
Kristiansson, K ;
Lederballe-Pedersen, O ;
Lindholm, LH ;
Nieminen, MS ;
Omvik, P ;
Oparil, S ;
Wedel, H .
LANCET, 2002, 359 (9311) :995-1003
[5]   Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA):: a multicentre randomised controlled trial [J].
Dahlöf, B ;
Sever, PS ;
Poulter, NR ;
Wedel, H ;
Beevers, DG ;
Caulfield, M ;
Collins, R ;
Kjeldsen, SE ;
Kristinsson, A ;
McInnes, GT ;
Mehlsen, J ;
Nieminen, M ;
O'Brien, E ;
Östergren, J .
LANCET, 2005, 366 (9489) :895-906
[6]  
Expert Committee on the Diagnosis and Classification of Diabetes Mellitus, 2003, DIABETES CARE, V26, DOI DOI 10.2337/DIACARE.26.2007.S5
[7]   Rising tide of cardiovascular disease in American Indians - The Strong Heart Study [J].
Howard, BV ;
Lee, ET ;
Cowan, LD ;
Devereux, RB ;
Galloway, JM ;
Go, OT ;
Howard, WJ ;
Rhoades, ER ;
Robbins, DC ;
Sievers, ML ;
Welty, TK .
CIRCULATION, 1999, 99 (18) :2389-2395
[8]  
Kelly R., 1989, J. Vasc. Med. Biol, VI, P142
[9]   THE STRONG HEART-STUDY - A STUDY OF CARDIOVASCULAR-DISEASE IN AMERICAN-INDIANS - DESIGN AND METHODS [J].
LEE, ET ;
WELTY, TK ;
FABSITZ, R ;
COWAN, LD ;
LE, NA ;
OOPIK, AJ ;
CUCCHIARA, AJ ;
SAVAGE, PJ ;
HOWARD, BV .
AMERICAN JOURNAL OF EPIDEMIOLOGY, 1990, 132 (06) :1141-1155
[10]  
Lee ET, 1998, AM J EPIDEMIOL, V147, P995, DOI 10.1093/oxfordjournals.aje.a009406